ArticleOpen forum infectious diseases2020
Investigation of Heartland Virus Disease Throughout the United States, 2013-2017.
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Article
- The 'teabag method': tick feeding protocol and the effects of tick feeding on hematological parameters in the canine host.Parasites & vectors · 2026Article
- Real-Time Polymerase Chain Reaction Systems for Detection and Differentiation of Unclassified Viruses of theMethods and protocols · 2025Article
- Advances in research on severe fever with thrombocytopenia syndrome virus.Frontiers in microbiology · 2025Review
- Heartland Virus Infection in Elderly Patient Initially Suspected of Having Ehrlichiosis, North Carolina, USA.Emerging infectious diseases · 2024Article
- Pathogenesis and virulence of Heartland virus.Virulence · 2024Review
- A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses.Journal of virology · 2024Article
- Neurological manifestations of ehrlichiosis among a cohort of patients: prevalence and clinical symptoms.BMC infectious diseases · 2024Article
- Heartland Virus Disease-An Underreported Emerging Infection.Microorganisms · 2024Review
- Tick-Borne Co-Infections: Challenges in Molecular and Serologic Diagnoses.Pathogens (Basel, Switzerland) · 2023Review
- The Lone Star tick, Amblyomma americanum, salivary factors exacerbate the clinical outcome of Heartland virus disease in a small animal model.Scientific reports · 2023Article
- Fatal Case of Heartland Virus Disease Acquired in the Mid-Atlantic Region, United States.Emerging infectious diseases · 2023Article
- Clinically differential diagnosis of human granulocytic anaplasmosis and severe fever with thrombocytopenia syndrome.Scientific reports · 2023Article
- The Lone Star Tick, Amblyomma americanum, salivary factors exacerbate the clinical outcome of Heartland virus disease in a small animal model.Research square · 2023Article
- Geographical distribution and pathogenesis of ticks and tick-borne viral diseases.Frontiers in microbiology · 2023Review
- Lethal severe fever with thrombocytopenia syndrome virus infection causes systemic germinal centre failure and massive T cell apoptosis in cats.Frontiers in microbiology · 2023Article
- Secondary hemophagocytic lymphohistiocytosis due to Heartland virus.BMJ case reports · 2022Article
- Isolation of Heartland Virus from Lone Star Ticks, Georgia, USA, 2019.Emerging infectious diseases · 2022Article
- Transovarial Transmission of Heartland Virus by Invasive Asian Longhorned Ticks under Laboratory Conditions.Emerging infectious diseases · 2022Article
- Reassortant Cache Valley Virus Associated With Acute Febrile, Nonneurologic Illness, Missouri.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeartland virus (HRTV) was first described as a human pathogen in 2012. From 2013 to 2017, the Centers for Disease Control and Prevention (CDC) implemented a national protocol to evaluate patients for HRTV disease, better define its geographic distribution, epidemiology, and clinical characteristics, and develop diagnostic assays for this novel virus.
methodsIndividuals aged ≥12 years whose clinicians contacted state health departments or the CDC about testing for HRTV infections were screened for recent onset of fever with leukopenia and thrombocytopenia. A questionnaire was administered to collect data on demographics, risk factors, and signs and symptoms; blood samples were tested for the presence of HRTV RNA and neutralizing antibodies.
resultsOf 85 individuals enrolled and tested, 16 (19%) had evidence of acute HRTV infection, 1 (1%) had past infection, and 68 (80%) had no infection. Patients with acute HRTV disease were residents of 7 states, 12 (75%) were male, and the median age (range) was 71 (43-80) years. Illness onset occurred from April to September. The majority reported fatigue, anorexia, nausea, headache, confusion, arthralgia, or myalgia. Fourteen (88%) cases were hospitalized; 2 (13%) died. Fourteen (88%) participants reported finding a tick on themselves in the 2 weeks before illness onset. HRTV-infected individuals were significantly older (
conclusionsHealth care providers should consider HRTV disease testing in patients with an acute febrile illness with either leukopenia or thrombocytopenia not explained by another condition or who were suspected to have a tickborne disease but did not improve following appropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.